Ask the Scholar
Page 21 of 26
I can add historical knowledge about this page.
Page image
OCR
FEB-15-96 THU 15:48 BSTN HUMAN RIGHTS INST. 617 266 0051
2-16-1996 :20PM
FROM KAHPAKUKI 613/010061
P.03
Salk Immunogen, Cont'd from page 1
After years of study in HIV-seropositive Individuals the
results this year have been published in Journal of Acquired
Immune Deficiency Syndrome (Vol. 7. Supplement 1, 1994),
happened to Salk before, the scientific establishment scoffed.
the Journal of Infectious Diseases (June 94). and elsewhere.
The Salk rationale is based on the Idea that the virus
The reports suggest that immunization with the HIV-1
persia due to an inadequate immune system response and
immunogen leads to an improvement of cell-mediated
that the body can be induced to generate a more effective
immune response against the virus, a slower rate of increase
response through vaccination. The mechanisms by which
in the amount of virus (i.e. viral load or viral burden), a
this may occur Include reducing the amount of circulating
slower decline in CD4+ T-cell percent, and a reduction in the
virus, improving recognition of variants of the virus,
enhancing the immune system's recognition of viral antigens
rate of clinical progression (the appearance of new symptoms
or opportunistic infections). In a double-blind, adjuvant-
and increasing support of the remaining T-cells. (See Salk,
controlled study, immune system, viral, and cellular effects
J., Prospects for the control of AIDS by immunizing
were observed in the first year following the start of
seropositive individuals, Nature, 327,473-476, 1987).
immunization with clinical effects seen in the second year.
[NOTE: antigens are substances that slimulate on immune
While the results individually are not all that remarkable, the
response. The immune system recognizes these substances as
concordance of all these markers, without exception, seem to
being foreign, and produces antibodies to fight them. The
be in the right direction,
antigen/antibody response is an important part of immunity.]
No serious adverse reactions to immunization have been
Since that time, we have been able to demonstrate in
observed in any of the studies conducted thus far.
several human trials the safety and immune-enhancing
In a double-blind, controlled study (Study 103), both the
properties of his HIV-1 Immunogen, made from the whole
killed Zairian strain of HIV.
pattern of change in viral burden and the incidence of
progression has been more favorable among those who
Salk's methodology involved culturing the live HIV-1
showed the most pronounced immune response following
virus to obtain sufficient amounts and then purifying it. It
immunization. Specifically, what was looked for was an
was then stripped of its envelope glycoprotein gp120. leaving
immunogen-specific cell-mediated immune response, Since
the rest of the antigens intact. Salk felt that we did not know
progression did not correlate with cell-mediated immune
enough about the active mane of the
1A
Page data
- Page
- 21
- Source index
- 0
- Type
- photo
- Media ID
- 42e27aa5bcfea8f8
- Size
- unknown
Document data
- ID
- 575017544
- Core
- doc
- Type
- document
DTO data
{
"id": "575017544",
"sourceUrl": "https://catalog.archives.gov/id/575017544",
"contentType": "document",
"title": "Search for a Cure",
"citationUrl": "https://catalog.archives.gov/id/575017544",
"collections": [
"Records of the Office of the Public Liaison (Clinton Administration)",
"Elizabeth (Julian) Potter's files"
],
"iiifBase": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"thumbnailUrl": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"largeImageUrl": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"imageCount": 26,
"hasImages": true,
"source": "import",
"hasTranscription": false
}
Context sent to Scholar
Document identity
{
"localId": "575017544",
"label": "Search for a Cure",
"core": "doc",
"dtoType": "document",
"citationUrl": "https://catalog.archives.gov/id/575017544"
}
Document source metadata
{
"id": "575017544",
"sourceUrl": "https://catalog.archives.gov/id/575017544",
"contentType": "document",
"title": "Search for a Cure",
"citationUrl": "https://catalog.archives.gov/id/575017544",
"collections": [
"Records of the Office of the Public Liaison (Clinton Administration)",
"Elizabeth (Julian) Potter's files"
],
"iiifBase": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"thumbnailUrl": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"largeImageUrl": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-001.jpg",
"imageCount": 26,
"hasImages": true,
"source": "import",
"hasTranscription": false
}
Document source extras
{
"url": "https://catalog.archives.gov/id/575017544",
"naId": 575017544,
"levelOfDescription": "fileUnit",
"otherTitles": [
"26437308-20230849S-026-011-2025"
],
"recordType": "description",
"ocrSource": "nara-archive"
}
Page context
{
"seq": 21,
"pageIndex": 0,
"type": "photo",
"url": "https://s3.us-east-1.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/wjc-opl/26437308/26437308-20230849S-026-011-2025/26437308-20230849S-026-011-2025-021.jpg",
"mediaId": "42e27aa5bcfea8f8",
"ocrText": "FEB-15-96 THU 15:48 BSTN HUMAN RIGHTS INST. 617 266 0051\n2-16-1996 :20PM\nFROM KAHPAKUKI 613/010061\nP.03\nSalk Immunogen, Cont'd from page 1\nAfter years of study in HIV-seropositive Individuals the\nresults this year have been published in Journal of Acquired\nImmune Deficiency Syndrome (Vol. 7. Supplement 1, 1994),\nhappened to Salk before, the scientific establishment scoffed.\nthe Journal of Infectious Diseases (June 94). and elsewhere.\nThe Salk rationale is based on the Idea that the virus\nThe reports suggest that immunization with the HIV-1\npersia due to an inadequate immune system response and\nimmunogen leads to an improvement of cell-mediated\nthat the body can be induced to generate a more effective\nimmune response against the virus, a slower rate of increase\nresponse through vaccination. The mechanisms by which\nin the amount of virus (i.e. viral load or viral burden), a\nthis may occur Include reducing the amount of circulating\nslower decline in CD4+ T-cell percent, and a reduction in the\nvirus, improving recognition of variants of the virus,\nenhancing the immune system's recognition of viral antigens\nrate of clinical progression (the appearance of new symptoms\nor opportunistic infections). In a double-blind, adjuvant-\nand increasing support of the remaining T-cells. (See Salk,\ncontrolled study, immune system, viral, and cellular effects\nJ., Prospects for the control of AIDS by immunizing\nwere observed in the first year following the start of\nseropositive individuals, Nature, 327,473-476, 1987).\nimmunization with clinical effects seen in the second year.\n[NOTE: antigens are substances that slimulate on immune\nWhile the results individually are not all that remarkable, the\nresponse. The immune system recognizes these substances as\nconcordance of all these markers, without exception, seem to\nbeing foreign, and produces antibodies to fight them. The\nbe in the right direction,\nantigen/antibody response is an important part of immunity.]\nNo serious adverse reactions to immunization have been\nSince that time, we have been able to demonstrate in\nobserved in any of the studies conducted thus far.\nseveral human trials the safety and immune-enhancing\nIn a double-blind, controlled study (Study 103), both the\nproperties of his HIV-1 Immunogen, made from the whole\nkilled Zairian strain of HIV.\npattern of change in viral burden and the incidence of\nprogression has been more favorable among those who\nSalk's methodology involved culturing the live HIV-1\nshowed the most pronounced immune response following\nvirus to obtain sufficient amounts and then purifying it. It\nimmunization. Specifically, what was looked for was an\nwas then stripped of its envelope glycoprotein gp120. leaving\nimmunogen-specific cell-mediated immune response, Since\nthe rest of the antigens intact. Salk felt that we did not know\nprogression did not correlate with cell-mediated immune\nenough about the active mane of the\n1A"
}